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Abstract 
Background: Hypertension  (HTN) affects approximately 25% of the UK population and is a leading cause of mortal‑
ity. Associated annual health care costs run into billions. National treatment guidance includes initial lifestyle advice, 
followed by anti‑hypertensive medication if blood pressure (BP) remains high. However, adoption and adherence 
to recommended exercise guidelines, dietary advice and anti‑hypertensive medication is poor. Four short bouts of 
isometric exercise (IE) performed 3 days per week (d/wk) at home elicits clinically significant reductions in BP in those 
with normal to high‑normal BP. This study will determine the feasibility of delivering personalised IE to patients with 
stage 1 hypertension for whom lifestyle changes would be recommended before medication within NHS primary 
care.
Methods: This is a randomised controlled feasibility study. Participants were 18+ years, with stage 1 hypertension, 
not on anti‑hypertensive medication and without significant medical contraindications. Trial arms will be standard 
lifestyle advice (control) or isometric wall squat exercise and standard lifestyle advice. Primary outcomes include the 
feasibility of healthcare professionals to deliver isometric exercise prescriptions in a primary care NHS setting and esti‑
mation of the variance of change in systolic BP. Secondary outcomes include accuracy of protocol delivery, execution 
of and adherence to protocol, recruitment rate, attrition, perception of intervention viability, cost, participant experi‑
ence and accuracy of home BP. The study will last 18 months. Sample size of 100 participants (50 per arm) allows 
for 20% attrition and 6.5% incomplete data, based upon 74 (37 each arm) participants (two‑sided 95% confidence 
interval, width of 1.33 and standard deviation of 4) completing 4 weeks. Ethical approval IRAS ID is 274676.
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Introduction
Background and rationale
Hypertension (≥ 140/90 mmHg) [1] affects approxi-
mately 1 in 4 people in the UK and is a leading modifiable 
risk factor for mortality [2]. As the most common long-
term health condition in the UK and a primary risk factor 
for mortality [2], hypertension is a serious health problem 
[3, 4]. With every 20 mmHg increase in systolic BP above 
115 mmHg and 10 mmHg increase in diastolic BP above 
75 mmHg, the risk of mortality from cardiovascular dis-
ease doubles [5]. Public Health England (PHE) suggests 
that there is an opportunity to prevent more than 9000 
heart attacks and at least 14,000 strokes over 3 years with 
better detection and management of high BP, high cho-
lesterol and atrial fibrillation [6]. Estimates indicate that 
the annual burden from conditions attributable to hyper-
tension is over £2 billion in England [4], with long-term 
care following a debilitating heart attack, stroke and/or 
vascular dementia often precipitated by hypertension 
costing substantially more [7, 8]. It has been suggested 
that over ten years, 45,000 quality adjusted life years and 
£850m could be saved if England achieved a 5 mmHg 
reduction in population systolic BP [4, 8]. In 2007, the 
NHS and PHE announced a drive to prevent thousands 
of heart attacks and strokes but highlighted the need for 
research into innovative lifestyle modifications to lower 
BP [4]. New personalised support for lifestyle changes 
[3], like our IE training prescription [9, 10], delivered by 
primary care allied health professionals could support 
this drive without directly adding to GP workload [11].
Standard care for hypertension
National guidance for the treatment of hypertension is 
graded from lifestyle intervention (i.e. advice about diet, 
weight management, exercise, alcohol intake) to phar-
macological therapy depending upon severity and dura-
tion of hypertension when other factors have been taken 
into account such as age, co-morbidity and the presence 
of target organ damage [1, 12]. The goal of antihyperten-
sive therapy is generally to reduce clinic BP to < 140/90 
mmHg, although recommended targets vary depend-
ing on age and co-morbidity [1, 13]. However, up to 50% 
of people fail to achieve their target BP [14, 15] mainly 
due to non-compliance (estimated 30–50% failing to 
comply at 6 and 12 months, respectively) [16, 17] with 
undesirable side effects of anti-hypertensive medication 
often cited in this context [18, 19].
Lifestyle interventions
The importance of lifestyle changes to aspects, such as 
diet and exercise habits for patients with hypertension 
in the absence of other risk factors should not be over-
looked [1, 20]. Additional treatment options are also in 
keeping with the UK government’s commitment to pro-
vide greater patient choice [21]. Whilst dietary strate-
gies can be effective, these are difficult to fully adopt and 
maintain [22, 23].
Evidence suggests that exercise may be as effective as 
medication in controlling BP [24–26] and it is often pro-
moted as a treatment option for those with stage 1 hyper-
tension (defined as a blood pressure of 140–159/90–99 
mmHg), without co-morbidity or other long-term con-
ditions [1, 27]. Current exercise guidelines for the pre-
vention and treatment of hypertension recommend that 
adults accumulate a mainstay of 30+ min of moderate 
intensity aerobic exercise on 5, but preferably all, days 
per week (d/wk), supplemented by moderate to vigorous 
resistance exercise 2–3 d/wk and general flexibility exer-
cise ≥ 2–3 d/wk [28, 29]. However, in a randomised con-
trolled trial, a long-term programme of aerobic exercise 
training failed to reduce clinic BP [30]. This may be due to 
poor adherence (e.g. 67%) to the relatively high amounts 
of aerobic exercise recommended [30, 31]. Furthermore, 
other studies have demonstrated attrition rates as high 
as 50% during traditional aerobic exercise interventions 
[32, 33]. Indeed, evidence typically suggests that a signifi-
cant challenge is the low adoption and high attrition rates 
associated with these guidelines [34]. Thus, effective and 
manageable lifestyle interventions with respect to exer-
cise remain an unmet clinical need [3]. It is suggested 
that to promote lifestyle exercise changes, patients need 
easily adopted, effective and manageable exercise inter-
ventions as a first line option for managing their BP.
Isometric exercise
Meta-analyses indicate that isometric exercise (IE) results 
in larger reductions in BP when compared with either 
aerobic and dynamic resistance exercise training [25, 
35] and has great potential to treat hypertension [10, 36] 
and improve cardiovascular health, which may reduce 
Discussion: Before the efficacy of this novel intervention to treat stage 1 hypertension can be investigated in any 
large randomised controlled trial, it is necessary to ascertain if it can be delivered and carried out in a NHS primary 
care setting. Findings could support IE viability as a prophylactic/alternative treatment option.
Trial registration: ISRCT N1347 2393, registered 18 August 2020
Keywords: Isometric exercise, Exercise, Hypertension, General practice, Feasibility study, COVID‑19
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mortality risk [37]. We have shown that IE can lower BP 
in people with both normal [9, 38] and high-normal (pre-
hypertensive) [10, 39] BP and therefore has the potential 
to be an effective lifestyle intervention for hypertension. 
IE involves holding a fixed position for a period of time; 
skeletal muscles are used but there is no movement, e.g. 
the wall squat which involves leaning against a wall in a 
seated position (Fig. 1).
Evidence suggests that IE offers distinct advantages 
over other forms of exercise [10, 36] making it a better 
lifestyle treatment for hypertension. A frequently cited 
barrier to exercise is lack of time [40, 41]. Though aero-
bic exercise guidelines recommend ≥ 150 min/week [42], 
it has been demonstrated that adherence is better with 
shorter bouts of exercise [43, 44]. Only 24 min of iso-
metric wall squat exercise a week are required to achieve 
clinically significant reductions in BP of 12/6 mmHg in 
pre-hypertensives [10]. Moreover, our evidence-based IE 
wall squat programme can be easily prescribed by health 
care providers and is very simple to execute regardless of 
age or physical ability [10, 45]. It does not require costly 
equipment or access to specialist facilities, does not 
require specific clothing, and most importantly, is eas-
ily performed at home [9, 10]. Empowering patients to 
manage their condition is key and use of short, simple, 
personalised exercise that can be carried out at home 
may enable this [46, 47]. Furthermore, our personalised 
exercise ‘prescription’ ensures optimal IE intensity is 
achieved, helping to improve confidence, motivation and 
patient adherence [40, 48].
Contextualising current findings
The importance of these findings is substantial [49] 
considering a 10 mmHg reduction in systolic BP and 
5-mmHg reduction in diastolic BP is associated with a 
40% lower risk of stroke and 30% lower risk of mortality 
from heart disease and other vascular causes throughout 
middle age [6]. Although we have consistently demon-
strated that IE can lower BP [10, 37, 38, 50], interpreta-
tion of the results, along with the findings of others is 
limited by small participant numbers [9, 10, 37, 51–56]. 
Isometric exercise may provide a new viable solution 
with respect to exercise for those with stage 1 hyperten-
sion, but evidence for the efficacy of IE in this clinical 
population is still not robust. Furthermore, this inter-
vention has never been tested within a NHS setting, nor 
confirmed in any large randomised control trials. This 
feasibility study was deemed necessary by the NIHR to 
determine uncertain parameters necessary to inform 
and justify the design and further funding of a large scale 
randomised controlled trial to evaluate the efficacy and 
mechanisms of isometric wall squat exercise to lower BP 
in stage 1 hypertensive NHS patients.
Objectives
The aim of the study is to determine the feasibility of 
delivering an individually tailored IE training programme 
to patients with stage 1 hypertension (defined as a clinic 
BP of 140–159/90–99 mmHg) for whom lifestyle changes 
would be recommended before pharmacological treat-
ment within a primary care NHS setting. Furthermore, 
the primary objectives are as follows:
1. To assess if healthcare professionals (e.g. nurses, 
health trainer, healthcare assistants, physiotherapists) 
can deliver isometric exercise prescriptions for stage 
1 hypertensive patients in a primary care NHS set-
ting
2. To estimate the variance in BP change, to enable 
sample size calculation for a definitive randomised 
controlled trial
The secondary objectives are as follows:
1. Evidence the fidelity of the study intervention with 
respect to healthcare professional delivery and 
patient completion of IE
2. Estimate short- (4 week) and medium-term (3 and 6 
month) adherence rates to IE intervention
3. Estimate recruitment and attrition rates at recruiting 
GP sites to inform future trials
4. Explore the willingness of GPs, secondary care clini-
cians and healthcare professionals to consider IE as a 
treatment option for patients, including barriers and 
facilitators for delivering and integrating this within 
an NHS care pathway for hypertension
Fig. 1 Isometric wall squat exercise
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5. Establish the cost and cost-utility of the IE interven-
tion compared to standard care for stage 1 hyperten-
sion
6. Understand participant experiences of undertak-
ing IE, adherence to the programme and continua-
tion. Additionally, explore possible negative effects of 
COVID-19 on recruitment rates and participation
7. To investigate the feasibility of using observed home 
blood pressure readings for remote monitoring
Trial design
Design
Multi-centre randomised controlled feasibility study.
Random allocation
Those that meet the inclusion criteria will be randomised 
to one of two groups in a 1:1 ratio. One hundred partici-
pants will be recruited; therefore, 50 participants will be 
allocated to each group.
Amendments due to COVID‑19 pandemic
As a result of the unprecedented spread of a novel coro-
navirus early in 2020, by mid-March the European region 
had become the epicentre of a COVID-19 pandemic 
[57]. An outcome of this was that many recently funded 
health projects using human participants, including this 
study, were required to re-evaluate their viability and 
where necessary revise their research design, methods 
and protocols in line with general Government and spe-
cific funder guidance (e.g. NIHR Restart Framework [58]) 
to help ensure the continued safety of research partici-
pants and personnel alike. The main changes made to this 
study are documented (identified in italics) to provide the 
reader with greater insight into how this research pro-
ject evolved to become fit for purpose as part of what has 
now become a new research normal.
Methods: participants, interventions and outcomes
Study setting
GP practices in the South East of England.
Eligibility criteria
Patients aged 18+ with stage 1 hypertension who are 
not yet on anti-hypertensive medication and without 
any significant medical condition that would contrain-
dicate their participation.
Exclusion criteria
Patients who are taking anti-hypertensive medication; 
have white coat hypertension (as evidenced by averaged 
home systolic BP < 135 mmHg); are unable to under-
take the study intervention (isometric exercise); have a 
previous history of diabetes mellitus (type 1 or type 2), 
known or suspected ischaemic heart disease (includ-
ing myocardial infarction and/or angina and/or coro-
nary revascularization procedure), moderate or severe 
stenotic or regurgitant heart valve disease, atrial or 
ventricular arrhythmia, stroke or transient ischaemic 
attack, aortic aneurysm and/or peripheral arterial dis-
ease, uncorrected congenital or inherited heart condi-
tion; have an estimated glomerular filtration rate < 45 
ml/min (calculated using CKD-EPI or MDRD formu-
lae, and taking most recent documented results); have 
a documented left ventricular ejection fraction < 45% 
and/or left ventricular hypertrophy (by either echo-
cardiography or standard ECG criteria, e.g. Sokolow-
Lyon); have a documented urine albumin to creatinine 
ratio > 3.5 mg/mmol; are unable to provide informed 
consent; are enrolled in another Clinical Trial of an 
Interventional Medicinal Product or Medical Device or 
other interventional study; and if female, are pregnant 
or currently breast feeding. Then finally, any medical 
condition that, in the opinion of the investigator, would 
make the participant unsuitable for the study.
Who will take informed consent?
Trained healthcare professionals will be obtaining 
informed consent via discussion on video call and com-
pletion via online software or hardcopy.
Interventions
Explanation for the choice of comparators
National guidance for patients newly diagnosed with 
stage 1 hypertension is two tiered and recommends that 
GP’s normally provide advice about potential lifestyle 
(non-pharmaceutical) changes that may help to reduce 
BP in the first instance before prescribing antihyper-
tensive medication [1]. As such, the comparator used 
in this study will be defined as ‘standard care lifestyle 
advice’. One potential issue raised during preliminary 
consultation with PPI members, the healthcare pro-
fessionals (including GP’s) in primary and consultants 
in secondary care was related to the concept of stand-
ard care lifestyle advice. It quickly became evident that 
there are differences in the quality and consistency of 
standard care lifestyle advice provided by primary care 
centres across the region (and indeed the UK). As such, 
it was agreed by the Project Management Group that 
for accurate comparison of the intervention (arm 1) 
with the control (arm 2), standard care lifestyle advice 
would need to be as consistent as possible across par-
ticipating sites. The best way to achieve this within the 
project time frame was to adhere to common published 
guidelines that would be given to all HCP’s and patients 
involved. As such, the project adopted an existing peer 
reviewed leaflet produced by the East Kent Hospitals 
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University NHS Foundation Trust (EKHUFT) entitled: 
High Blood Pressure (Hypertension) - Information 
for Patients from the Department of Renal (Kidney) 
Medicine.
Intervention description
Standard care lifestyle advice (arm 1 — control) or iso-
metric wall squat exercise training with standard care 
lifestyle advice (arm 2). Figure  2 shows flow-chart of 
selection of participants and interventions.
The following lifestyle information will be provided to 
all participants taking part in the study.
1. Lifestyle changes that are recommended for people 
with high blood pressure include the following:
(a) Salt intake. The average salt intake in the UK is 
9 g/day. The recommended daily salt intake for 
an adult is 5 to 6 g/day. Reducing the amount 
of salt in your food lowers blood pressure and 
makes blood pressure lowering medications 
more effective. Although stopping adding salt 
to your food when cooking or at the table is 
important, 80% of the salt we eat is already pre-
sent in food when we buy it — so called ‘hid-
den salt’. Understanding food labelling can help 
you see where these hidden sources of salt are 
found.
(b) Healthy diet. You should follow a diet that is 
rich in fresh fruit and vegetables and low in sat-
urated fat.
(c) Weight. You should try to maintain a body 
mass index between 20 and 25 kg/m2. Those 
with BMI greater than 30 kg/m2 and high blood 
pressure should definitely try to lose weight to 
achieve a BMI of 30 kg/m2 or below. See BMI 
chart at the end of this leaflet.
(d) Alcohol consumption. You should adhere to the 
current UK limit of less than 14 units per week. 
If you do regularly drink as much as 14 units 
in a week try to spread your drinking evenly 
over three days or more. One unit of alcohol is 
equivalent to half-pint of average strength beer, 
a small glass of wine (125 ml), or a single pub 
measure of spirits. Remember that stronger 
beers (such as continental lager) and larger 
glasses of wine (175 ml or 250 ml) will contain 
more units.
(e) Exercise. You should try to exercise at a level 
that makes you breathless for at least 30 min 
three times a week, although more is recom-
mended if possible. A variety of different types 
of exercise — aerobic/endurance (for example 
running) and resistance (for example weights) 
— both appear to be equally helpful in reducing 
blood pressure.
2. For more information on lifestyle modification visit 
the Blood Pressure UK website:
(a) www. blood press ureuk. org/ Blood Press urean 
dyou/ Yourl ifest yle
The full leaflet ‘High Blood Pressure (Hypertension) - 
Information for Patients from the Department of Renal 
(Kidney) Medicine’ is presented as an additional file (see 
Additional file 1).
Participants allocated to the intervention arm 2 will be 
required to attend their GP surgery to perform an incre-
mental isometric wall squat test. This test will be deliv-
ered by the designated healthcare professional (HCP) 
previously trained in the delivery of this protocol. Upon 
arrival participants will be familiarised with a simple rat-
ing of perceived exertion scale validated specifically for 
use with isometric exercise [59]. Following this, they will 
be fitted with a wireless heart rate monitor chest strap 
and wrist watch (Sigma PC 15.11, Neustadt/Weinstraße, 
Germany) and MIE clinical goniometer (MIE Medical 
Research Ltd., Leeds, UK), which will be attached to the 
participant’s left leg using elastic Velcro straps. The ful-
crum will be aligned with the lateral epicondyle of the 
femur, and the moving arm is placed on the lateral mid-
line of the femur using the greater trochanter for refer-
ence and the stationary arm on the lateral midline of the 
fibula using the lateral malleolus and fibular head for 
reference. A spirit level will be attached to the stationary 
arm to ensure that the lower leg is kept vertical during 
exercise (Fig. 3) [37].
The participant will then be asked to perform a con-
tinuous isometric wall squat test in stages of increasing 
intensity, which is determined by manipulating knee 
joint angle with the internal angle between the femur and 
fibula measured. Based upon the work of Goldring et al. 
[53], the first stage begins at 135° of knee flexion, and 
participants are instructed to hold this position for 2 min. 
HR is measured continuously throughout the incremen-
tal test with HR recorded every 5 s during the last 30–0 
s of each 2-min increment. Wall (measured as floor to 
coccyx height) and floor (measured as wall to back of the 
heels) positions are also recorded (cm) in the final 10 s 
of each increment. At the end of each increment, partici-
pants will be asked to rate their perceived exertion to give 
the healthcare professional an indication of how close 
they are to finishing the test. Once each stage is complete 
the knee joint angle will be decreased by 10°. The angle is 
then decreased every 2 min until the participant reaches 
the end of the 95° stage or can no longer maintain the 
knee joint angle within 5° of the target value (volitional 
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Assessment 2 (remote) (Week 4, Day 30-33)
• Concomitant medications
• Home blood pressure measures collected and 
observed blood pressure taken
• Heart rate
• Participant questionnaires
• IE experience survey
• Invitation to focus group
Assessment 2 (remote) (Week 4, Day 30-33)
• Concomitant medications
• Home blood pressure measures 




Telephone follow up call 1 (within 7 days of 
IIET visit)
Remote Screening Assessment
(Day -14 to Day 0)
• Informed consent
• Medical history, concomitant medication
• IE ability test
• Determine eligibility
Assessment 4 – 6 month follow up (remote) (+/- 7 days)
• Participant questionnaires
• Home blood pressure measures collected and observed blood 
pressure taken
• Heart rate
CONTROL ARM PARTICIPANTS WILL BE OFFERED AN IE PROGRAMME AT THIS POINT
In the case of informed
consent signed on a
physical copy and posted to 
site, delay further screening 
activity until received.
Participants identified at GP practice sites and invited by letter, email or through study advertising 
ARM 2 – ISOMETRIC EXERCISE (n=50)
Standard care lifestyle advice plus 3 sessions of 
IE per week 
ARM 1 – CONTROL (n=50)
Standard care lifestyle advice only
Remote Baseline Assessment (Day 1)
• Observed blood pressure




Assessment 3 – 3 month follow up (remote) (+/- 7 days)
• Participant questionnaires
• Home blood pressure measures collected and observed blood 
pressure taken
• Heart rate
Home blood pressure monitoring 5 days 
(Between Day -7 and 0)
IIET visit (within 7 days of the Remote 
Baseline assessment)
Fig. 2 Trial flow chart
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fatigue). The HCP’s were instructed to maintain a good 
dialogue (providing as much encouragement as was nec-
essary) with the participant throughout, to ensure they 
stay calm and relax their breathing to avoid the Valsalva 
manoeuvre, to watch closely for any signs of physical dis-
tress and not to hesitate to stop the test immediately if 
they feel the participant’s health is at risk [60].
Based upon each participant’s test data, knee joint 
angle is plotted against the mean HR for the last 30 s of 
each incremental stage. Since an accurate IE wall squat 
prescription requires data from at least 3 complete stages, 
any participant unable to achieve this will be classed as a 
screen failure and informed that they will not be able to 
take part in the study. The relationship between param-
eters is then used to calculate the specific knee joint angle 
required to elicit a target HR. The target HR selected for 
training is 95%  HRpeak, with  HRpeak defined as the mean 
HR of the final 30 s achieved during the incremental test 
[60]. Additionally, the individual target heart rate range 
(THRR) will be established using the 95% reference inter-
val [61].
During the 10-min data analysis period (performed 
remotely by the study research assistant), the patient 
will be taken through the participant information and 
their personal IE training diary (used to record the HR 
and RPE data from each training session performed 
in the home) to ensure that they fully understand what 
is required of them throughout the 6-month training 
period. At this stage, the patient will also be issued with 
their own HR monitor, shown how to work it and given a 
written instruction sheet for future reference.
A goniometer is not deemed practical for participant 
measurement of knee joint angle during home-based 
training; therefore, a simple device called the ‘Bend and 
Squat’ is used to align a participant’s feet and back into 
the correct position for a given wall squat knee joint 
angle (Fig. 4) [55].
Once the device is set to the participants personal wall 
and floor measurements necessary to replicate the angle 
required to elicit 95%  HRpeak, they will then be asked to 
squat in this set position as a fidelity check to ensure 
that it equates to their specific training knee joint angle. 
Fig. 3 Goniometry of the knee
Fig. 4 Bend and Squat device used to determine knee joint angle 
during wall squat exercise
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In the unlikely event that it is necessary, a slight adjust-
ment to the wall height can be used to achieve the cor-
rect knee joint angle prescribed. Before the client leaves 
the surgery to commence their training, it will be ensured 
that they are completely confident with the information 
they have received. Participants will then given a web link 
(USB stick if required) containing video instructions of 
how to set up their HR monitor, use the Bend and Squat 
device to perform a IE training session and how to record 
the necessary training data in their diaries. They will also 
be provided with the study research assistant contact tel-
ephone and e-mail helpline address for use during office 
hours.
All IE training sessions thereafter will be completed 
in the home. Participants will use their Bend and Squat 
device to perform an IE training session composed 
of 4 bouts of 2-min wall squats with 2 min recovery in 
between each bout [60]. Participants will be instructed 
to perform three IE training sessions a week, ideally on 
alternate days to allow for adequate between session 
recovery. During the IE training sessions, the HR value 
displayed at the end of each 4 × 2-min wall squat along 
with their RPE will be recorded for subsequent analysis. 
If the mean HR of the four exercise bouts deviates from 
the prescribed THRR on two consecutive sessions in the 
first week of IE training (acting as a fidelity check), the 
knee joint angle and thus their Bend and Squat set-up 
will be altered accordingly based upon further interpola-
tion of their HR/knee joint angle relationship.
Criteria for discontinuing or modifying allocated 
interventions
Modification of the isometric exercise prescription will 
be made if appropriate, after the participant’s first week 
of exercise training, as part of the IE protocol fidelity 
assessment.
Strategies to improve adherence to interventions
Participants will receive reminder text or email mes-
sages to help adherence to standard care advice collecting 
home blood pressure measurements and isometric exer-
cise training.
A bespoke automated reminder system was developed 
in order to manage the different types of reminders and 
different periodicity of these.
Arm 1 (control) will receive monthly reminders to 
adhere to the standard care lifestyle advice given by their 
HCP at Baseline. Arm 2 (intervention) will also receive 
monthly standard care lifestyle advice in addition to three 
IE training reminders per week, for the duration of the 
study.
At follow up timepoints 4 weeks, 3 months and 6 
months, all participants will receive a 24-h reminder to 
start taking their home blood pressure.
Relevant concomitant care permitted or prohibited 
during the trial
Exclusion criteria states the participants should not be 
taking anti-hypertensive medications whilst taking part 
in the trial.
Provisions for post‑trial care
The participants in the control arm will be offered an iso-
metric exercise intervention after they have completed 
their time in the study. The GP practice will oversee par-
ticipant’s general care throughout the trial and partici-




1. Feasibility of isometric exercise prescription assessed 
using qualitative data from healthcare professional 
focus groups at month 11/12 of 18 month study
2. Feasibility of isometric exercise intervention and 
study assessed using qualitative data from partici-
pants at month 7 and 11 of 18 month study
3. Variance of blood pressure changes from baseline 
using participant blood pressure data at week 4 and 
months 3 and 6 of intervention
4. Sample size for a definitive randomised controlled 
trial, calculated using estimate of variability of evi-
dence of effect on systolic blood pressure change 
at week 1 and months 3 and 6 (of the intervention) 
from the feasibility study and the minimum clinically 
important difference
5. Estimate of the treatment difference in systolic BP 
change from baseline and 80 and 95% confidence 
intervals to provide preliminary assessment of ben-
efit, and aid decision whether to proceed to a con-
firmatory RCT at the end of the feasibility study
Secondary
1. Fidelity of the isometric exercise prescription meas-
ured using prescription competency assessment data 
(ability to carry out incremental isometric exercise 
test and an accurate prescription of individual IE 
intensity - knee joint angle translated into bend and 
squat measurements) from HCP intervention train-
ing at month 3 of 18 month study
2. Fidelity of the delivery of the isometric exercise pre-
scription by HCP assessed through observation 
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(study coordinator) of the first Incremental Isomet-
ric Exercise Test (IIET) and subsequent prescrip-
tion delivered at site from month 3 to month 5 of 18 
month study
3. Fidelity of the isometric exercise prescription defined 
by participant 95% peak heart rate falls within their 
THRR in at least two-thirds of all training sessions at 
say 7–10 of intervention
4. Short and medium-term adherence rates recorded as 
those adhering to isometric exercise intervention at 
week 4, month 3 and month 6 of intervention
 5. Recruitment and attrition rates from data collected 
at sites at month 10 and month 15 of 18 month 
study
 6. GPs and healthcare professionals’ attitudes to iso-
metric exercise as a treatment option for patients, 
measured using remote focus groups and telephone 
interviews at month 11/12 of 18 month study
 7. Cost and cost-utility of the isometric exercise inter-
vention using healthcare resource use data and 
quality-adjusted life years (QALYs) at month 15 (or 
last patient follow up) of 18 month study
 8. Participant experiences of undertaking isometric 
exercise using participant isometric exercise expe-
rience surveys at week 4 of intervention
 9. Effect of COVID-19 on recruitment rates and par-
ticipation using participant focus groups or tel-
ephone calls at month 7 and 11 of 18 month study
 10. Feasibility of using observed home blood pressure 
readings for remote blood pressure monitoring, 
using participant blood pressure data and observa-
tions from the measures at day 1, week 4, month 3 
and month 6 of intervention
Participant timeline
The participant timeline is presented in Table 1.
Sample size
Review of current literature revealed few IE studies in 
a hypertensive population. These studies were small (n 
< 25), conducted under different conditions to the pro-
posed study, and showed low precision and large variabil-
ity in estimates of the standard deviation (SD). A sample 
size of 100 participants, 50 per arm, will be used in the 
study. Allowing for 20% attrition and 6.5% incomplete 
data, 74 participants (37 in each arm) will have com-
pleted change measures at 4 weeks. This is in line with 
the recommended sample size of 70 to estimate key 
parameters from external pilot RCTs [62]. A sample size 
of 74 produces a two-sided 95% confidence interval with 
a width of 1.33 when the standard deviation is 4. This 
estimate of 4 has been taken from a previous study (N 
= 24) [10]. The sample size confidence interval has been 
calculated using Pass11 software (PASS 11. NCSS, LLC. 
Kaysville, UT, USA, www. ncss. com).
Recruitment
Participants will be identified opportunistically through 
patient database searches and invited to participate. The 
study will also be advertised with ethically approved 
advertising materials, in participating GP practices, 
with electronic adverts on their websites, social media 




Random permuted blocks will be used within stratifica-
tion (of site and age), ensuring that treatments are bal-
anced at the end of every strata block. There are two 
stratification groups for age; these are age 18–49 years 
and ≥ 50 years. It is anticipated that between two to six 
primary care sites in South East England will be included 
in the study.
Concealment mechanism
Participants will be allocated to either the control or iso-
metric exercise arm using a third-party supplier of ran-
domisation services [63]. This internet-based service 
allows investigators to randomise patients from any-
where in the world through a web browser.
Implementation
The investigators will implement the allocation created 
by the online randomisation software [63].
Assignment of interventions: blinding
This feasibility study was intended to replicate real life 
NHS practice where patients would be fully aware of any 
medical intervention prescribed by their healthcare pro-
fessional. Therefore, the healthcare professionals (deliv-
ering the exercise intervention) and the participants/
patients (performing the exercise) were not blinded to 
the allocated lifestyle intervention arms.
Data collection and management
Plans for assessment and collection of outcomes
The success of intervention delivery by healthcare pro-
fessionals in a primary NHS healthcare settings will be 
determined using both qualitative data (remote) and the 
heart rate data recorded by the participants at the end 
of each isometric wall squat bout x4 per session over the 
3 sessions completed in the first week using a wireless 
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heart rate monitor and chest strap (Sigma PC 15.11, Neu-
stadt/Weinstraße, Germany). The average HR calculated 
from the first 3 sessions will then be compared against 
the individuals’ target training HR (calculated as 95% 
of  HRpeak measured during the individuals incremental 
isometric exercise test IIET) with an acceptable target 
heart rate range (THRR) of 76–111% of heart rate peak 
[60]. Perceptions of intervention delivery by healthcare 
professionals will be explored in qualitative focus groups 
(remote). The focus group questions for both healthcare 
professionals and participants were guided by the work 
of O’Cathain et al. [64] on the use of qualitative research 
in feasibility studies for randomised controlled trials. The 
groups will discuss the intervention content and delivery 
and the trial design, conduct and processes. For profes-
sionals, the core questions will be the following: What 
are your views on how the isometric exercise was imple-
mented? Is the study design acceptable? How did the 
planned recruitment practices work in practice? Are the 
proposed process and outcome measures valid for this 
group of service users?
Any change in BP following the IE intervention will be 
determined using the home blood pressure data (meas-
ured using an automated upper arm blood pressure 
monitor [Omron M3 Intellisense, Kyoto, Japan] at weeks 
4, 12, and 24) recorded in the participants diaries and 









IIET visit (within 




— IE arm only 
(within 7 days of 
IIET visit)
Assessment 
2 day 28–33 
(remotely)
Assessment 3 
month 3 (± 7 
days) (remotely)
Assessment 4 
month 6 (± 7 
days) (remotely)
Medical history X X
Concomitant 
medication





X X X X
IE ability test X
Incremental 
IE test and IE 
programme pro‑





AE review X X X X
Diet question‑
naire
X X X X
Exercise ques‑
tionnaire
X X X X
Quality of life 
questionnaire
X X X X
Collection of 
IE exercise 




X X X X
Collection of 
home blood pres‑
sure and heart 
rate readings
X (between 
day 7 and 
day 1)
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comparing this against their observed baseline (recorded 
at day 1). This data will also be used to estimate BP vari-
ance by calculating systolic BP change from baseline at 
each endpoint. An estimate of the difference in change 
from baseline between the isometric exercise and control 
group will be calculated with 80% and 95% confidence 
intervals.
Accuracy of IE protocol delivery will be determined 
using data from three fidelity assessments; the first being 
healthcare professional competency checks administered 
during their isometric exercise prescription training; the 
second being expert observation/evaluation of at least 
the first IIET delivered by each HCP; and then finally, 
by third party examination of the first week of heart rate 
data recorded in the study diaries of each HCP’s specific 
participants, with average HR calculated from the first 3 
sessions being compared against the individuals target 
training HR as described above.
Execution of the IE training protocol in the home will 
be assessed for each individual participant at the end of 
the first week by checking to see if their mean training 
heart rate per week falls within target heart rate range/
reference interval (76–111%) data for weeks 4, 12 and 24 
will now be assessed at the end of the 6-month training 
period. An estimate of the short- (4 week) and medium-
term (3 and 6 month) adherence rates to IE training will 
be based upon the data collected from participant diaries 
to calculate the proportion of participants completing ≥ 
two thirds of all IE sessions (12, 36 and 72) at each time 
point respectively. Patient recruitment and participant 
attrition rates will be calculated based upon the average 
number of participants recruited per week over the 7 
month recruitment period and the number of withdraw-
als from the study once the last follow-up call to the last 
participant has been made.
Participant experiences of IE will be assessed through 
a quantitative online survey conducted at week 4. All 
participants receiving the IE intervention will be invited 
to take part in one of two focus groups (remote) to draw 
out respondents’ attitudes, feelings, beliefs, and experi-
ences regarding the intervention [65]. The core focus 
group questions for participants were also directed by 
the guidelines for using qualitative research in feasibility 
studies [64]. What are your views on how you applied the 
isometric exercise intervention? What are your thoughts 
on how the study was conducted? What do you think are 
important outcomes to consider in a full trial? This will 
also be used as an opportunity to explore possible negative 
effects of COVID-19 on recruitment rates and participa-
tion. These groups will be held at month 4 and month 8 
of the recruitment period with 6–8 participants in each 
group. One focus group will also be undertaken with 
healthcare professionals involved in the intervention 
delivery at the end of the recruitment period to explore 
views and experiences of the IE intervention. Lay and 
professional members of the research team will co-pro-
duce the topic guide and co-facilitate the focus groups. 
The focus groups are proposed to last for between 60 and 
90 min. The groups will be digitally recorded and tran-
scribed. Telephone interviews (n = 5–10) will be con-
ducted with stakeholders from GP practices which are 
not recruitment sites and not involved in the interven-
tion delivery to explore the willingness of GPs and pri-
mary care healthcare professionals to consider IE as a 
viable treatment option for patients, including barriers 
and facilitators for delivering and integrating this within 
an NHS care pathway for hypertension.
The economic evaluation of delivering the IE interven-
tion will be calculated once the last follow-up call has 
been made to the last participant and will be estimated 
from Healthcare resource use data and quality-adjusted 
life years (QALYs). Since QALYs are the primary outcome 
of the economic evaluation, utility values will be obtained 
from patients’ responses to each of the EQ-5D-5L at the 
beginning of the intervention and at week 4 and months 
3 and 6 after the intervention [66, 67].
New insight into the accuracy of home BP measure-
ments to monitor changes in BP will be based upon the 
BP data (observed and home readings) recorded (at base-
line assessment, day 1; assessment 2, week 4; assessment 
3, month 3; and assessment 4, month 6) in the participant 
diaries, along with expert evaluation of the participants 
ability to carry out the measure.
Plans to promote participant retention and complete 
follow‑up
Participant adherence will be measured as outcome data 
including the number of IE sessions completed. Comple-
tion of at least 8 of 12 sessions between baseline and the 
4 week timepoint will be deemed adherence to the inter-
vention. The percentage of completed IE sessions that 
meet the required target HR threshold will be calculated. 
The percentage of participants that deviate from protocol 
will be recorded to assess fidelity to the IE programme. 
The rate of healthcare professionals that pass the compe-
tency assessment after the half-day training session will 
be calculated.
Data management
Data entered directly into paper case report forms is con-
sidered as source data, additional source documentation 
includes participant study diaries, online questionnaires 
and focus group/interview audio recordings and tran-
scripts. Data from case report forms and participant dia-
ries will be entered manually into the database allowing 
for data monitoring and cleansing. Questionnaire data 
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will be received and directly accessible online by only 
research team members who have the appropriate access. 
Case report forms will be shared with the coordinating 
centre via password secured email and a copy retained 
securely at site. A unique code will be produced for each 
participant and used on all corresponding documenta-
tion and files, to ensure anonymity.
Confidentiality
Only anonymised data will be shared with the coordi-
nating centre for analysis. Electronic files with personal 
information will be password protected and stored on 
the university partner networks in folders that can only 
be accessed by the research team. Access to the data 
collected during the project (including any participant 
personal data) will be restricted to the research team, 
and data will not be shared with anyone else. Personal 
information that may enable the service user to be iden-
tified will be removed from interview and focus group 
transcripts.
Any personal data will be destroyed on completion of 
the project. The coded data will be stored for five years 
following the completion of the study, when it will be 
destroyed.
Statistical methods
Statistical methods for primary and secondary outcomes
Quantitative data analysis
Descriptive statistics will be used to assess primary and 
secondary process outcomes such as recruitment rates, 
adherence rates and completeness of data. Exercise 
adherence will be compared with outcomes to inform 
compliance criteria in the full study. In a definitive 
study, the primary outcome — change from baseline in 
systolic BP — will be analysed using analysis of covari-
ance (ANCOVA), with a fixed treatment effect allowing 
adjustments for baseline values, centre, sex and age. This 
model will be used to estimate differences between the 
arms and confidence intervals from the feasibility study. 
Eighty percent and 95% confidence intervals will be cal-
culated. Data from the IE experience questionnaires will 
be transferred to Stata/IC version 16 and analysed using 
descriptive statistics.
Qualitative data analysis
Thematic analysis of focus group/interview transcripts 
will be carried out using Braun and Clarke’s [68] six stage 
model using NVivo version 11 qualitative data analy-
sis software (QSR International Pty Ltd. [2015] NVivo, 
https:// www. qsrin terna tional. com/ nvivo- quali tative- 
data- analy sis- softw are/ home). Drawing on Sweeney 
et al.’s [69] notion that the service user researcher unique 
perspective should be preserved rather than subsumed, 
the process will involve multiple members (including 
public co-applicants) of the project team. Inductive the-
matic analysis of focus group/interview transcripts will 
be carried out using NVivo version 11 (QSR International 
Pty Ltd. [2015] NVivo, https:// www. qsrin terna tional. 
com/ nvivo- quali tative- data- analy sis- softw are/ home). 
The process will involve reading and re-reading the tran-
scripts and noting down initial ideas. Then the tran-
scripts will be coded. Data extracts will be collated within 
each code and then codes ordered into potential themes. 
Subsequently, these themes will then be reviewed and 
refined. Ongoing analysis will refine the specifics of each 
theme and identify any themes which have not previ-
ously been recognised. Deviant case analysis will be used 
to ensure that perspectives that diverged from dominant 
trends are not overlooked.
Methods in analysis to handle protocol non‑adherence 
and any statistical methods to handle missing data
Missing values will be estimated using a combination of 
last observation carry forward and baseline observation 
carried forward (where only baseline data are available) 
in the secondary analysis of intention to treat.
Plans to give access to the full protocol, participant 
level‑data and statistical code
Anonymised data will be made available to researchers at 
universities, NHS organisations or other healthcare pro-
viders where the sharing of data has a clear defined pur-
pose and its use will be of benefit to wider society.
Oversight and monitoring
Composition of the coordinating centre and trial steering 
committee
Delivery of the project is a collaboration between the 
Section of Sport, Exercise & Rehabilitation Sciences, 
Canterbury Christ Church University (CCCU), the Cen-
tre for Health Services Studies, University of Kent (UKC) 
and East Kent Hospitals University Foundation Trust 
(EKHUFT).
Two groups were established to provide appropri-
ate oversight of the study and ensure this is maintained 
from various perspectives, the Study Steering Committee 
(SSC) and the Project Management Group (PMG).
The SSC is comprised of at least 75% independent 
members and includes the project co-leads, an inde-
pendent statistician, a health economist, a clinician with 
expertise in hypertension/clinical trials/primary care, an 
exercise specialist and two independent lay members. 
The SSC meets tri-monthly to critically oversee progress, 
outputs, deliverables and governance of the project; have 
oversight of delivery of the study on behalf of the funder 
to ensure achievement of study objectives within agreed 
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timelines; ensure the protection of rights and safety of 
study participants; regularly review of ongoing project 
data; and periodically review of safety data to ensure 
patient safety throughout [70]. In doing so, the SSC 
reports directly to the funder. The SSC will consider the 
need for any interim analysis based on reports received 
and may consider data emerging from other related stud-
ies and make recommendations for this study based on 
these. The SSC will also consider whether further time or 
funding is required for any aspect of the study and advise 
where best this may be obtained.
The PMG is comprised of 2 co-chief investigators, 4 
co-applicants (including the project manager), 1 stat-
istician, 1 health economist, 2 public co-applicants, 1 
research facilitator and 1 study coordinator [70]. The 
members of PMG were responsible for the elaboration of 
this protocol and meets fortnightly with the purpose of 
maintaining clear oversight of study delivery according to 
the protocol, original grant application and subsequent 
changes; assessing the progress of the study and identify-
ing any barriers to completion; agreeing mitigation plans 
and actions for any barriers to study completion, e.g. 
the current Covid-19 pandemic; providing advice to the 
Chief Investigators; ensuring the protection of rights and 
safety of study participants; and reporting on study pro-
gress to the SSC and funder.
The organizational study chart will include the spon-
sor EKHUFT, the SSC, the PMG, the two research units; 
UKC as lead on Qualitative data (health economics, focus 
group, interviews, patient participant involvement etc.) 
and CCCU as lead on quantitative data (intervention 
delivery, fidelity and patient outcomes etc.), the clinical 
research lead and the investigators at each primary care 
recruitment sites in SE England.
Composition of the data monitoring committee, its role 
and reporting structure
A data monitoring committee is not needed for this study 
because the intervention is non-invasive with minimal 
risk of harm.
Adverse event reporting and harms
An adverse event (AE) is any untoward medical occur-
rence in a study participant. A serious adverse event 
(SAE) is any untoward medical occurrence that: results in 
death, is life-threatening, requires inpatient hospitalisa-
tion or prolongation of existing hospitalisation, results in 
persistent or significantly disability/incapacity or consists 
of a congenital anomaly or birth defect. Other ‘important 
medical events’ may also be considered serious if they 
jeopardise the participant or require an intervention to 
prevent one of the above consequences.
Only AEs resulting (definitely or probably) from study 
procedures or the intervention will be collected by the 
research team and recorded in the participant’s medical 
records. These may be volunteered by the participant or 
discovered by the investigator or healthcare professional 
conducting study visits/follow-up telephone calls. They 
should be documented throughout the entirety of the 
study from randomisation until month 6 of intervention. 
Each AE will be evaluated by the Principal Investigator 
(PI) for seriousness, causality and expectedness.
A list of potential isometric exercise specific AEs was 
provided to the HCPs/investigators.
All SAEs will be recorded within 24 h of knowledge of 
the event. The SAE will be evaluated by the PI and when 
necessary, in collaboration with the Chief investigator 
(CI) (highly experienced renal consultant). The CI will 
report all SAEs to the Sponsor and the Research Ethics 
Committee within the conditions of ethical approval. The 
Study Steering Committee will periodically review safety 
data to ensure patient safety throughout.
Frequency and plans for auditing trial conduct
Regular monitoring will be performed by the Study 
Coordinator to evaluate compliance with the protocol. 
Monitoring will verify that the study is conducted, and 
data are generated, documented and reported in compli-
ance with the protocol and the applicable regulatory and 
national policy requirements [70]. Any data issues will be 
addressed by raising data queries for GP sites to resolve 
where possible, following this on-site monitoring will be 
undertaken. Direct access will be granted to authorised 
representatives from the Sponsor, host institution and 
the regulatory authorities to permit trial-related moni-
toring, audits and inspections - in line with participant 
consent.
Plans for communicating important protocol amendments 
to relevant parties (e.g. trial participants, ethical 
committees)
Any substantial amendments to the protocol or other 
study documents may require review and approval by the 
Research Ethics Committee (REC) before the changes 
can be implemented to the study. Where amendments 
are required, NHS HRA and REC procedures will be 
followed, i.e. any amendment will be shared directly via 
email with participating sites. Sites will be asked to con-
firm receipt of the amended documents.
Discussion
Systematic isometric wall squat exercise, which employs 
the large muscle mass of the quadriceps, has been 
shown to be an effective means of lowering resting BP. 
In a recent relatively small-scale study, Taylor et al. [10] 
showed that the magnitude of BP reduction following 4 
weeks of isometric wall squat exercise in unmedicated 
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high normal participants was greater than when the 
same intervention was completed by those with BP in 
the normal range [9]. It was postulated that this IE inter-
vention may exert a greater antihypertensive effect in 
patients with more severe hypertension such as those 
diagnosed with stage 1 hypertension. The clinically sig-
nificant BP reduction observed was also greater than the 
average BP reduction achieved with a single, standard 
dose anti-hypertensive drug [71] and is associated with 
reduced cardiovascular mortality [5]. However, before 
the efficacy of this novel intervention to treat stage 1 
hypertension can be investigated in any large-scale ran-
domised controlled trial, it is first necessary to ascertain 
if it can be delivered and carried out as intended in (as 
ultimately envisioned) an NHS primary care setting. 
If it can, and patient adherence is found to be equal or 
better than that documented for other forms of lifestyle 
invention and resting BP is shown to either decrease or 
stay the same following the IE intervention, then the find-
ings of this feasibility study will support the viability of IE 
as both a prophylactic and alternative treatment option 
for thousands of NHS patients wishing to avoid antihy-
pertensive drug therapy. Importantly, the results of this 
study will determine uncertain parameters needed to 
design a substantive efficacy study, including the vari-
ance in BP change needed for sample size calculation, 
the ability to deliver the intervention as intended in pri-
mary care, recruitment rates, and participant acceptabil-
ity and compliance. Moreover, the economic analysis in 
this feasibility study will determine the acceptability of 
resource use and utility measures in this setting, establish 
the cost of the IE intervention programme and conduct 
some preliminary modelling to explore potential cost 
effectiveness, prior to a full economic evaluation of the IE 
intervention programme in the planned definitive trial. 
The follow-on study will be a randomised, controlled effi-
cacy study pending additional funding. This study will 
determine uncertain parameters needed to design a sub-
stantive trial; variance of the primary outcome measure 
needed for sample size calculation, ability to deliver the 
intervention as intended in primary care, recruitment 
rates and participant acceptability and compliance.
Whilst the advent of Covid-19 has presented a sig-
nificant challenge, primarily in terms of reliably deliver-
ing and evaluating a novel exercise training intervention 
remotely, it has also provided a valuable opportunity to 
evaluate alternate methodological approaches/new pro-
tocols that may not otherwise have occurred, e.g. the fea-
sibility of using observed patient home BP readings for 
remote monitoring as opposed to clinic measurements. 
Since the current pandemic shows little sign of abating, 
this additional information might help to inform the 
research design of similar studies planned for delivery 
during these exceptional times.
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